Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-25 @ 10:15 PM
NCT ID:
NCT03010358
Group ID:
EG001
Title:
Phase 2 and MTD (800 mg Entospletinib Daily)
Description:
Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) according to dose level 2 (400 mg twice daily). Patients also receive obinutuzumab IV on days 1, 2, 8 and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
5
Serious Number At Risk:
17
Other Number Affected:
17
Other Number At Risk:
17
Study:
NCT03010358
Results Section:
NCT03010358
Adverse Events Module:
NCT03010358